Should lung biopsies be performed in patients with severe asthma?

European Respiratory Review

Volumn 24, Issue 137, 2015, Pages 525-539

  Doberer, Daniel ^a,b   Trejo Bittar, Humberto E ^c   Wenzel, Sally E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; TRANSCRIPTION FACTOR RUNX2;

AIRWAY; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALLERGIC PNEUMONITIS; ARTICLE; ASTHMA; BASEMENT MEMBRANE; BRONCHIOLE; BRONCHOSCOPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHURG STRAUSS SYNDROME; CLINICAL DECISION MAKING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG MEGADOSE; EOSINOPHILIA; GRANULOMATOSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG PARENCHYMA; LYMPHOCYTIC INFILTRATION; NEUTROPHIL; PERSONAL EXPERIENCE; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TH2 CELL; TRANSBRONCHIAL BIOPSY; TREATMENT INDICATION; VIDEO ASSISTED THORACOSCOPIC SURGERY; ADVERSE EFFECTS; BIOPSY; DIFFERENTIAL DIAGNOSIS; LUNG; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ASTHMA; BIOPSY; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84940664168     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0045-2015     Document Type: Article

References (121)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention, revised 2014. Date last accessed: May 20, 2015. Date last updated: April 2015. www.ginasthma.org.
2. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716–725.
3. Wenzel SE. A plea to abandon asthma as a disease concept. Lancet 2006; 368: 705.
4. Cruschmann H. Ueber bronchiolitis exsudativa und ihr Verhaeltnis zum asthma nervosum. Dtsch Arch Klin Med 1882; 32: 1–34.
5. Dolhnikoff M, da Silva LF, de Araujo BB, et al. The outer wall of small airways is a major site of remodeling in fatal asthma. J Allergy Clin Immunol 2009; 123: 1090–1097.
6. Wenzel SE, Busse WW. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119: 14–21.
7. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355–1360.
8. Hyde DM, Hamid Q, Irvin CG. Anatomy, pathology, and physiology of the tracheobronchial tree: emphasis on the distal airways. J Allergy Clin Immunol 2009; 124: Suppl. S72–S77.
9. van den Berge M, ten Hacken NH, Cohen J, et al. Small airway disease in asthma and COPD: clinical implications. Chest 2011; 139: 412–423.
10. Burgel PR, Bergeron A, de Blic J, et al. Small airways diseases, excluding asthma and COPD: an overview. Eur Respir Rev 2013; 22: 131–147.
11. Bonini M, Usmani OS. The role of the small airways in the pathophysiology of asthma and chronic obstructive pulmonary disease. Ther Adv Respir Dis 2015 [In press DOI: 10.1177/1753465815588064].
12. van der Wiel E, ten Hacken NH, Postma DS, et al. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol 2013; 131: 646–657.
13. Macklem PT, Mead J. Resistance of central and peripheral airways measured by a retrograde catheter. J Appl Physiol 1967; 22: 395–401.
14. Woolcock AJ, Vincent NJ, Macklem PT. Frequency dependence of compliance as a test for obstruction in the small airways. J Clin Invest 1969; 48: 1097–1106.
15. Levine G, Housley E, MacLeod P, et al. Gas exchange abnormalities in mild bronchitis and asymptomatic asthma. N Engl J Med 1970; 282: 1277–1282.
16. Despas PJ, Leroux M, Macklem PT. Site of airway obstruction in asthma as determined by measuring maximal expiratory flow breathing air and a helium-oxygen mixture. J Clin Invest 1972; 51: 3235–3243.
17. Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298: 1277–1281.
18. McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. Eur Clin Respir J 2014; 1: 25898.
19. Contoli M, Bousquet J, Fabbri LM, et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy 2010; 65: 141–151.
20. Collard P, Njinou B, Nejadnik B, et al. Single breath diffusing capacity for carbon monoxide in stable asthma. Chest 1994; 105: 1426–1429.
21. Wenzel SE, Vitari CA, Shende M, et al. Asthmatic granulomatosis: a novel disease with asthmatic and granulomatous features. Am J Respir Crit Care Med 2012; 186: 501–507.
22. Ueda T, Niimi A, Matsumoto H, et al. Role of small airways in asthma: investigation using high-resolution computed tomography. J Allergy Clin Immunol 2006; 118: 1019–1025.
23. Busacker A, Newell JD Jr, Keefe T, et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 2009; 135: 48–56.
24. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218–224.
25. Niimi A, Matsumoto H, Amitani R, et al. Effect of short-term treatment with inhaled corticosteroid on airway wall thickening in asthma. Am J Med 2004; 116: 725–731.
26. Walker C, Gupta S, Hartley R, et al. Computed tomography scans in severe asthma: utility and clinical implications. Curr Opin Pulm Med 2012; 18: 42–47.
27. Carroll N, Elliot J, Morton A, et al. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993; 147: 405–410.
28. Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J 1997; 10: 292–300.
29. Faul JL, Tormey VJ, Leonard C, et al. Lung immunopathology in cases of sudden asthma death. Eur Respir J 1997; 10: 301–307.
30. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332–336.
31. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997; 100: 44–51.
32. Minshall EM, Hogg JC, Hamid QA. Cytokine mRNA expression in asthma is not restricted to the large airways. J Allergy Clin Immunol 1998; 101: 386–390.
33. Taha RA, Minshall EM, Miotto D, et al. Eotaxin and monocyte chemotactic protein-4 mRNA expression in small airways of asthmatic and nonasthmatic individuals. J Allergy Clin Immunol 1999; 103: 476–483.
34. Balzar S, Wenzel SE, Chu HW. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J 2002; 20: 254–259.
35. Kraft M, Djukanovic R, Wilson S, et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 1505–1510.
36. Kraft M, Martin RJ, Wilson S, et al. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999; 159: 228–234.
37. Andersson CK, Bergqvist A, Mori M, et al. Mast cell-associated alveolar inflammation in patients with atopic uncontrolled asthma. J Allergy Clin Immunol 2011; 127: 905–912.
38. Balzar S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am J Respir Crit Care Med 2011; 183: 299–309.
39. Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156: 737–743.
40. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001–1008.
41. Brown HM. Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet 1958; 2: 1245–1247.
42. Pavord ID, Brightling CE, Woltmann G, et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353: 2213–2214.
43. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144–2148.
44. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167: 199–204.
45. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113: 101–108.
46. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315–323.
47. Torgerson DG, Ampleford EJ, Chiu GY, et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet 2011; 43: 887–892.
48. Siroux V, Basagaña X, Boudier A, et al. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J 2011; 38: 310–317.
49. Wu W, Bleecker E, Moore W, et al. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol 2014; 133: 1280–1288.
50. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388–395.
51. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 1189–1197.
52. De Boever EH, Ashman C, Cahn AP, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol 2014; 133: 989–996.
53. Moore WC, Fitzpatrick AM, Li X, et al. Clinical heterogeneity in the severe asthma research program. Ann Am Thorac Soc 2013; 10: Suppl, S118–S124.
54. Bratton DL, Price M, Gavin L, et al. Impact of a multidisciplinary day program on disease and healthcare costs in children and adolescents with severe asthma: a two-year follow-up study. Pediatr Pulmonol 2001; 31: 177–189.
55. Peytremann-Bridevaux I, Arditi C, Gex G, et al. Chronic disease management programmes for adults with asthma. Cochrane Database Syst Rev 2015; 5: CD007988.
56. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.
57. Sheshadri A, Hoffman EA, Castro M. Can computed tomography help us identify asthmatic phenotypes? J Allergy Clin Immunol 2014; 133: 739–740.
58. Gupta S, Hartley R, Khan UT, et al. Quantitative computed tomography-derived clusters: redefining airway remodeling in asthmatic patients. J Allergy Clin Immunol 2014; 133: 729–738.
59. Montaudon M, Lederlin M, Reich S, et al. Bronchial measurements in patients with asthma: comparison of quantitative thin-section CT findings with those in healthy subjects and correlation with pathologic findings. Radiology 2009; 253: 844–853.
60. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748.
61. Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19: 25–32.
62. Trahan S, Hanak V, Ryu JH, et al. Role of surgical lung biopsy in separating chronic hypersensitivity pneumonia from usual interstitial pneumonia/idiopathic pulmonary fibrosis: analysis of 31 biopsies from 15 patients. Chest 2008; 134: 126–132.
63. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44: 585–596.
64. Hoffmann RM, Kruis W. Rare extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 140–147.
65. Frankel SK, Schwarz MI. The pulmonary vasculitides. Am J Respir Crit Care Med 2012; 186: 216–224.
66. Urisman A, Jones KD. Pulmonary pathology in connective tissue disease. Semin Respir Crit Care Med 2014; 35: 201–212.
67. Allen TC. Pathology of small airways disease. Arch Pathol Lab Med 2010; 134: 702–718.
68. Riscili BP, Wood KL. Noninvasive pulmonary Aspergillus infections. Clin Chest Med 2009; 30: 315–335.
69. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis – state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37: Suppl. 3, S225–S264.
70. Breekveldt-Postma NS, Erkens JA, Aalbers R, et al. Extent of uncontrolled disease and associated medical costs in severe asthma – a PHARMO study. Curr Med Res Opin 2008; 24: 975–983.
71. Ivanova JI, Bergman R, Birnbaum HG, et al. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol 2012; 129: 1229–1235.
72. Accordini S, Bugiani M, Arossa W, et al. Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol 2006; 141: 189–198.
73. Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009; 9: 24.
74. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22: 470–477.
75. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119: 405–413.
76. Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. J Allergy Clin Immunol 1972; 49: 329–336.
77. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23–43.
78. Stanford RH, Gilsenan AW, Ziemiecki R, et al. Predictors of uncontrolled asthma in adult and pediatric patients: analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). J Asthma 2010; 47: 257–262.
79. Demoly P, Annunziata K, Gubba E, et al. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012; 21: 66–74.
80. Boulet LP, Vervloet D, Magar Y, et al. Adherence: the goal to control asthma. Clin Chest Med 2012; 33: 405–417.
81. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002; 19: 246–251.
82. Chanez P, Wenzel SE, Anderson GP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007; 119: 1337–1348.
83. Han Q, Luo Q, Xie JX, et al. Diagnostic yield and postoperative mortality associated with surgical lung biopsy for evaluation of interstitial lung diseases: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2015; 149: 1394–1401.
84. Kreider ME, Hansen-Flaschen J, Ahmad NN, et al. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann Thorac Surg 2007; 83: 1140–1144.
85. Good JT Jr., Kolakowski CA, Groshong SD, et al. Refractory asthma: importance of bronchoscopy to identify phenotypes and direct therapy. Chest 2012; 141: 599–606.
86. Groeben H, Grosswendt T, Silvanus M, et al. Lidocaine inhalation for local anaesthesia and attenuation of bronchial hyper-reactivity with least airway irritation. Effect of three different dose regimens. Eur J Anaesthesiol 2000; 17: 672–679.
87. Wahidi MM, Jain P, Jantz M, et al. American College of Chest Physicians consensus statement on the use of topical anesthesia, analgesia, and sedation during flexible bronchoscopy in adult patients. Chest 2011; 140: 1342–1350.
88. Workshop summary and guidelines: investigative use of bronchoscopy, lavage, and bronchial biopsies in asthma and other airway diseases. J Allergy Clin Immunol 1991; 88: 808–814.
89. Humbert M, Robinson DS, Assoufi B, et al. Safety of fibreoptic bronchoscopy in asthmatic and control subjects and effect on asthma control over two weeks. Thorax 1996; 51: 664–669.
90. Moore WC, Evans MD, Bleecker ER, et al. Safety of investigative bronchoscopy in the Severe Asthma Research Program. J Allergy Clin Immunol 2011; 128: 328–336.
91. Payne D, McKenzie SA, Stacey S, et al. Safety and ethics of bronchoscopy and endobronchial biopsy in difficult asthma. Arch Dis Child 2001; 84: 423–426.
92. Ravini M, Ferraro G, Barbieri B, et al. Changing strategies of lung biopsies in diffuse lung diseases: the impact of video-assisted thoracoscopy. Eur Respir J 1998; 11: 99–103.
93. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
94. Nguyen W, Meyer KC. Surgical lung biopsy for the diagnosis of interstitial lung disease: a review of the literature and recommendations for optimizing safety and efficacy. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30: 3–16.
95. Woods AQ, Lynch DA. Asthma: an imaging update. Radiol Clin North Am 2009; 47: 317–329.
96. Samejima J, Tajiri M, Ogura T, et al. Thoracoscopic lung biopsy in 285 patients with diffuse pulmonary disease. Asian Cardiovasc Thorac Ann 2015; 23: 191–197.
97. Seeger W, Adir Y, Barbera JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: Suppl., D109–D116.
98. Huber H, Koessler K. The pathology of bronchial asthma. Arch Intern Med 1922; 30: 689–760.
99. Saetta M, Turato G. Airway pathology in asthma. Eur Respir J 2001; 18: Suppl. 34, 18s–23s.
100. Trejo Bittar HE, Yousem SA, Wenzel SE. Pathobiology of severe asthma. Annu Rev Pathol 2015; 10: 511–545.
101. Jenkins HA, Cool C, Szefler SJ, et al. Histopathology of severe childhood asthma: a case series. Chest 2003; 124: 32–41.
102. Ordoñez CL, Khashayar R, Wong HH, et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med 2001; 163: 517–523.
103. Gordon IO, Husain AN, Charbeneau J, et al. Endobronchial biopsy: a guide for asthma therapy selection in the era of bronchial thermoplasty. J Asthma 2013; 50: 634–641.
104. Kanoh S, Tanabe T, Rubin BK. IL-13-induced MUC5AC production and goblet cell differentiation is steroid resistant in human airway cells. Clin Exp Allergy 2011; 41: 1747–1756.
105. Kuyper LM, Pare PD, Hogg JC, et al. Characterization of airway plugging in fatal asthma. Am J Med 2003; 115: 6–11.
106. Aikawa T, Shimura S, Sasaki H, et al. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 1992; 101: 916–921.
107. Ordoñez C, Ferrando R, Hyde DM, et al. Epithelial desquamation in asthma: artifact or pathology? Am J Respir Crit Care Med 2000; 162: 2324–2329.
108. Jeffery PK, Laitinen A, Venge P. Biopsy markers of airway inflammation and remodelling. Respir Med 2000; 94: Suppl F, S9–S15.
109. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: S28–S38.
110. Chu HW, Halliday JL, Martin RJ, et al. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am J Respir Crit Care Med 1998; 158: 1936–1944.
111. Chu HW, Balzar S, Westcott JY, et al. Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition. Clin Exp Allergy 2002; 32: 1558–1565.
112. James AL, Elliot JG, Jones RL, et al. Airway smooth muscle hypertrophy and hyperplasia in asthma. Am J Respir Crit Care Med 2012; 185: 1058–1064.
113. Kaminska M, Foley S, Maghni K, et al. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. J Allergy Clin Immunol 2009; 124: 45–51.
114. Bentley JK, Hershenson MB. Airway smooth muscle growth in asthma: proliferation, hypertrophy, and migration. Proc Am Thorac Soc 2008; 5: 89–96.
115. Haley KJ, Sunday ME, Wiggs BR, et al. Inflammatory cell distribution within and along asthmatic airways. Am J Respir Crit Care Med 1998; 158: 565–572.
116. Balzar S, Chu HW, Strand M, et al. Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am J Respir Crit Care Med 2005; 171: 431–439.
117. de Magalhães Simões S, dos Santos MA, da Silva Oliveira M, et al. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin Exp Allergy 2005; 35: 602–611.
118. Sur S, Crotty TB, Kephart GM, et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis 1993; 148: 713–719.
119. Chanez P, Bourdin A, Vachier I, et al. Effects of inhaled corticosteroids on pathology in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1: 184–190.
120. Nguyen LT, Lim S, Oates T, et al. Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respir Med 2005; 99: 200–207.
121. Ogata-Suetsugu S, Maeyama T, Takeshita M, et al. A case of diffuse large B-cell lymphoma of the lung demonstrating diffuse ground-glass shadows. Ann Thorac Cardiovasc Surg 2011; 17: 591–594.